Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Reply to Dr. Ricceri letter

Abstract

We thank Ricceri et al. for their comments (1) and interest in our study (2). Despite the recent advances in prevention and treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, these two chronic infections still represent the most common cause of chronic liver disease. Dermatologists are frequently encountering patients with psoriatic disease who have concomitant HBV or HCV infection in daily clinical practice.

Dr Ricceri provided in his letter further long-term follow-up data (60 months) on the use of etanercept or adalimumab in 17 psoriatic patients affected by past HBV infection or chronic HCV infection.

This article is protected by copyright. All rights reserved.

http://ift.tt/2p8TKK7